Abstract
This article deals with new migraine therapy, monoclonal antibodies against calcitonin gene related peptide (CGRP) and its receptor. The review represents a brief discussion of CGRP biological eff ects in the peripheral and central nervous system, and the role of CGRP in the migraine pathogenesis. Data of systematic reviews of randomized clinical research about the effi cacy and safety of monoclonal antibodies against CGRP (fremanezumab, eptinezumab and galkanezumab) and its receptor (erenumab) in patients with episodic and chronic migraine are included and analyzed. The results of fi ve-year use of erenumab in clinical research and in real practice are discussed and compared.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
